Luye Pharma Group Ltd - Asset Resilience Ratio
Luye Pharma Group Ltd (LUP) has an Asset Resilience Ratio of 5.92% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Luye Pharma Group Ltd (LUP) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Luye Pharma Group Ltd's Asset Resilience Ratio has changed over time. See LUP total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Luye Pharma Group Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Luye Pharma Group Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.90 Billion | 5.92% |
| Total Liquid Assets | €1.90 Billion | 5.92% |
Asset Resilience Insights
- Limited Liquidity: Luye Pharma Group Ltd maintains only 5.92% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Luye Pharma Group Ltd Industry Peers by Asset Resilience Ratio
Compare Luye Pharma Group Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Henan Newland Pharmaceutical Co. Ltd. A
SHE:301277 |
Drug Manufacturers - Specialty & Generic | 31.63% |
|
Hainan Shuangcheng Pharmaceut
SHE:002693 |
Drug Manufacturers - Specialty & Generic | 3.29% |
Annual Asset Resilience Ratio for Luye Pharma Group Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Luye Pharma Group Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 5.29% | €1.57 Billion ≈ $1.83 Billion |
€29.61 Billion ≈ $34.62 Billion |
-5.96pp |
| 2023-12-31 | 11.25% | €2.87 Billion ≈ $3.35 Billion |
€25.49 Billion ≈ $29.80 Billion |
-2.03pp |
| 2022-12-31 | 13.28% | €3.22 Billion ≈ $3.77 Billion |
€24.25 Billion ≈ $28.35 Billion |
-0.32pp |
| 2021-12-31 | 13.60% | €3.07 Billion ≈ $3.59 Billion |
€22.58 Billion ≈ $26.40 Billion |
+6.13pp |
| 2020-12-31 | 7.47% | €1.54 Billion ≈ $1.80 Billion |
€20.63 Billion ≈ $24.12 Billion |
-7.35pp |
| 2019-12-31 | 14.82% | €2.86 Billion ≈ $3.35 Billion |
€19.31 Billion ≈ $22.58 Billion |
-3.36pp |
| 2018-12-31 | 18.19% | €3.19 Billion ≈ $3.73 Billion |
€17.54 Billion ≈ $20.50 Billion |
-5.75pp |
| 2017-12-31 | 23.93% | €2.58 Billion ≈ $3.01 Billion |
€10.76 Billion ≈ $12.58 Billion |
-1.59pp |
| 2016-12-31 | 25.52% | €2.35 Billion ≈ $2.75 Billion |
€9.21 Billion ≈ $10.76 Billion |
-- |
About Luye Pharma Group Ltd
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and X… Read more